Twin Tree Management LP reduced its stake in Hologic, Inc. (NASDAQ:HOLX – Free Report) by 14.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,934 shares of the medical device supplier after selling 6,301 shares during the quarter. Twin Tree Management LP’s shares in Hologic were worth $2,957,000, according to its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of HOLX. Massmutual Trust Co. FSB ADV increased its stake in shares of Hologic by 24.7% in the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment supplier’s stock worth $54,000 after acquiring an additional 137 shares in the last quarter. Graypoint LLC increased its stake in shares of Hologic by 3.9% in the first quarter. Graypoint LLC now owns 3,871 shares of the medical equipment supplier’s stock worth $302,000 after acquiring an additional 147 shares in the last quarter. Arizona State Retirement System increased its stake in shares of Hologic by 0.3% in the fourth quarter. Arizona State Retirement System now owns 67,319 shares of the medical equipment supplier’s stock worth $4,810,000 after acquiring an additional 172 shares in the last quarter. Lincoln National Corp increased its stake in shares of Hologic by 4.0% in the fourth quarter. Lincoln National Corp now owns 4,675 shares of the medical equipment supplier’s stock worth $334,000 after acquiring an additional 178 shares in the last quarter. Finally, Allworth Financial LP increased its stake in shares of Hologic by 39.3% in the fourth quarter. Allworth Financial LP now owns 634 shares of the medical equipment supplier’s stock worth $45,000 after acquiring an additional 179 shares in the last quarter. 94.73% of the shares are held by hedge funds and other institutional investors.

Hologic stock return

NASDAQ:HOLX opened Friday at $78.11. The stock has a market cap of $18.23 billion, a price-to-earnings ratio of 39.85, a price-to-earnings growth ratio of 2.60 and a beta of 0.99. The company’s 50-day simple moving average is $74.26 and its 200-day simple moving average is $74.80. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $82.45. The company has a quick ratio of 3.29, a current ratio of 3.97 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX – Get Free Report) last released its quarterly earnings results on Thursday, May 2. The medical device supplier reported $1.03 EPS for the quarter, topping the consensus estimate of $0.98 by $0.05. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The company’s revenue for the quarter was down 0.8% compared to the year-ago quarter. In the prior-year quarter, the company reported $1.06 EPS. As a group, research analysts predict that Hologic, Inc. will post 4.08 EPS for the current year.

Wall Street analysts weigh in

Several research analysts have commented on the stock. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research note on Friday, May 3. Needham & Company LLC affirmed a “buy” rating and gave a $90.00 price target on shares of Hologic in a research note on Friday, May 3. JPMorgan Chase & Co. increased their price target on shares of Hologic from $85.00 to $91.00 and gave the stock an “overweight” rating in a research note on Friday, May 3. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and raised their price target on the stock from $80.00 to $95.00 in a research note on Wednesday, April 3. Finally, Argus increased their price target on shares of Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, May 9. Five research analysts have rated the stock with a hold rating and eight have rated it with a buy rating. Based on data from MarketBeat.com, Hologic currently has a consensus rating of “Moderate Buy” and an average price target of $85.55.

Read our latest analysis on Hologic

Insider activity

In other news, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction on Wednesday, July 17. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the sale, the Director now owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The sale was disclosed in a document filed with the SEC, accessible at this link . In other news, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction on Wednesday, July 17. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the sale, the Director now owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The sale was disclosed in a document filed with the SEC, accessible at this link . Also, CEO Stephen P. Macmillan sold 3,672 shares of the company’s stock in a transaction on Wednesday, July 17. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the sale, the CEO now owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The disclosure for this sale can be found here. Company insiders own 1.75% of the company’s stock.

Company Profile Hologic

(Free Report)

Hologic, Inc. develops, manufactures and markets diagnostic products, medical imaging systems and surgical products to advance women’s health through early detection and treatment. The company operates in four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. It offers Aptima molecular diagnostic assays to detect infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus and human cytomegalovirus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test to help physicians assess the risk of preterm birth.

Read further

Get news and reviews for Hologic Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings on Hologic and related companies with MarketBeat.com’s FREE daily email newsletter.